Public Sector Pension Investment Board Grows Position in Arrowhead Pharmaceuticals, Inc. $ARWR

Public Sector Pension Investment Board boosted its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 25.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 539,336 shares of the biotechnology company’s stock after acquiring an additional 110,950 shares during the period. Public Sector Pension Investment Board owned about 0.39% of Arrowhead Pharmaceuticals worth $18,602,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also added to or reduced their stakes in the company. State of Wyoming lifted its position in shares of Arrowhead Pharmaceuticals by 5.6% in the 3rd quarter. State of Wyoming now owns 9,519 shares of the biotechnology company’s stock worth $328,000 after purchasing an additional 504 shares during the period. Arizona State Retirement System raised its stake in Arrowhead Pharmaceuticals by 1.9% in the third quarter. Arizona State Retirement System now owns 32,661 shares of the biotechnology company’s stock worth $1,126,000 after buying an additional 620 shares in the last quarter. CWM LLC raised its stake in Arrowhead Pharmaceuticals by 6.7% in the third quarter. CWM LLC now owns 12,179 shares of the biotechnology company’s stock worth $420,000 after buying an additional 764 shares in the last quarter. Resona Asset Management Co. Ltd. lifted its holdings in Arrowhead Pharmaceuticals by 8.7% during the second quarter. Resona Asset Management Co. Ltd. now owns 11,218 shares of the biotechnology company’s stock worth $180,000 after buying an additional 900 shares during the period. Finally, Salomon & Ludwin LLC bought a new stake in Arrowhead Pharmaceuticals during the 3rd quarter valued at $34,000. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on ARWR shares. Royal Bank Of Canada boosted their price target on Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an “outperform” rating in a research report on Thursday, December 11th. Bank of America boosted their price objective on shares of Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Chardan Capital raised their target price on shares of Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the company a “buy” rating in a research note on Wednesday, January 7th. Piper Sandler reaffirmed an “overweight” rating and issued a $110.00 price target (up from $100.00) on shares of Arrowhead Pharmaceuticals in a report on Tuesday, January 13th. Finally, The Goldman Sachs Group upped their price target on Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 7th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, Arrowhead Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $81.67.

Insider Activity at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, CEO Christopher Richard Anzalone sold 13,187 shares of the business’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $66.10, for a total transaction of $871,660.70. Following the sale, the chief executive officer owned 3,792,739 shares in the company, valued at approximately $250,700,047.90. The trade was a 0.35% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Mauro Ferrari sold 7,530 shares of the firm’s stock in a transaction dated Friday, December 26th. The stock was sold at an average price of $70.00, for a total value of $527,100.00. Following the completion of the transaction, the director owned 69,053 shares of the company’s stock, valued at approximately $4,833,710. The trade was a 9.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 510,836 shares of company stock worth $33,603,060 in the last quarter. 3.60% of the stock is owned by insiders.

Trending Headlines about Arrowhead Pharmaceuticals

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Early reports show a “strong start” to REDEMPLO commercialization, which supports near-term revenue traction and helps explain buying interest despite mixed guidance from some analysts. ARWR: Strong Start for REDEMPLO Commercialization
• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and a $100 price target while raising several multi‑year estimates (notably FY2028–FY2030 upside and some quarterly lifts), signaling confidence in Arrowhead’s longer-term pipeline and commercialization prospects — a bullish catalyst for investors focused on growth potential. HC Wainwright Reaffirms Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
• Neutral Sentiment: Short‑interest data reported zero shares and NaN changes for mid‑February (likely a reporting/data anomaly). Current short‑interest ratio is shown as 0.0 days — this item appears to have no actionable impact on supply/demand given the inconsistent figures.
• Negative Sentiment: Zacks Research cut multiple near‑term and longer‑term EPS forecasts (Q2–Q4 2026 and FY2026–FY2028), lowering Q2–Q4 2026 quarter estimates and materially reducing FY2026 and FY2027 forecasts. Those downward revisions add pressure to near‑term earnings expectations and may weigh on sentiment for value/earnings‑driven traders.

Arrowhead Pharmaceuticals Stock Up 2.3%

NASDAQ:ARWR opened at $63.82 on Friday. The company has a current ratio of 3.38, a quick ratio of 3.38 and a debt-to-equity ratio of 0.29. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $9.57 and a twelve month high of $76.76. The company has a market cap of $8.94 billion, a PE ratio of 41.71 and a beta of 1.21. The company’s 50 day moving average is $67.03 and its two-hundred day moving average is $45.26.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings results on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.38). The company had revenue of $264.03 million during the quarter, compared to analysts’ expectations of $225.66 million. Arrowhead Pharmaceuticals had a return on equity of 35.64% and a net margin of 18.54%.The company’s quarterly revenue was up 10461.3% on a year-over-year basis. During the same period in the prior year, the business posted ($1.39) EPS. Analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.